Online telehealth company Hims and Hers Health is launching its weight-loss membership and treatment plans in the United ...

Online telehealth company Hims and Hers Health HIMS.N is launching its weight-loss membership and treatment plans in the UK ...

The move into the UK weight-loss category has been facilitated by the acquisition earlier this year of Zava, a London-based ...

Hims Hers Health Inc (NYSE:HIMS) stock fell 4.4% Wednesday after U.S. lawmakers introduced legislation that could significantly impact the company’s fastest-growing product category.

Hims & Hers Health stock has seen its fair value estimate trimmed from about $46.00 to roughly $44.36 per share, even as analysts grow more optimistic about its long term revenue trajectory. Stronger ...

Hims & Hers Health ($HIMS) is strengthening its position in the UK with the launch of weight-loss programs. This launch will ...

Online telehealth company Hims and Hers Health is launching weight-loss membership and treatment plans in the UK. The new service will offer drugs such as Novo Nordisk's Wegovy and Eli Lilly's ...

One of largest U.S. telehealth providers expects to ride wave of exploding demand for weight-loss drug semaglutide when it ...

・Retail traders ranked Novo Nordisk as the strongest long-term obesity play in a 1,100-vote poll. ・Users pointed to emerging drug pipelines, GLP-1 expansion and rising M&A pressure across the sector. ...

Detailed price information for Hims & Hers Health Inc (HIMS-N) from The Globe and Mail including charting and trades.

Eli Lilly LLY announced that it has lowered the price of single-dose vials of its blockbuster obesity drug, Zepbound ...

The dramatic stock slump, which puts Novo Nordisk at a historically cheap valuation, reflects investor concern over future sales growth and competition, particularly from rival Eli Lilly & Co.